This mini-theme contains six stories of health technology assessment (HTA) impact from member agencies of The International Network of Agencies for Health Technology Assessment (INAHTA), which were originally shared at the 2015 and 2016 INAHTA Congresses. The INAHTA impact story sharing is an innovative network activity where member agency representatives share experiences of HTA impact in a loosely structured story format. Through this process, members gain insights from other agencies on new ways of thinking about and approaching HTA impact assessment. A guide is provided to members to prepare their story, and the best story receives the David Hailey Award for Best Impact Story. This mini-theme contains stories of HTA impact from six member agencies in different parts of the world: the Health Assessment Division of the Ministry of Public Health (Uruguay), the Institute of Quality and Efficiency in Health Care (Germany), the Health Information and Quality Authority (Ireland), the Finnish Office for Health Technology Assessment (Finland), the Australian Safety and Efficacy Register of New Interventional Procedures-Surgical (Australia), and the Institut national d'excellence en santé et en services sociaux (Canada). Across the papers, common themes emerge about the importance of appropriate engagement of stakeholders and the broadening scope of HTA beyond reimbursement decision making.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S0266462317001076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exit interviews from two randomised placebo-controlled phase 3 studies with caregivers of young children with autism spectrum disorder.
Front Child Adolesc Psychiatry
June 2024
IM Franchise Department, Les Laboratoires SERVIER, Global Value, Access & Pricing, Suresnes, France.
Introduction: Autism spectrum disorder (ASD) is characterised by difficulty with social communication and restricted, repetitive patterns of behaviour. This study aimed to improve understanding of the ASD patient experience with the treatment (bumetanide) regarding the changes in core symptoms and to assess changes considered as meaningful. To achieve this, qualitative interviews were conducted with caregivers of patients in two phase 3 clinical trials (NCT03715153; NCT03715166) of a novel ASD treatment.
View Article and Find Full Text PDFClinical Microbiology: where do we stand?
Front Antibiot
June 2024
Department of Public Health Policy, School of Public Health, University of West Attica, Athens, Greece.
Clinical Microbiology has developed during the last 100 years, simultaneous with the discovery of microorganisms as causes of infections. Globalization and One Health determine present needs whereas molecular biology, automation, artificial intelligence, and bioinformatics are new tools that characterize the new developments in the field.
View Article and Find Full Text PDFHospital-based health technology assessment (HTA) in Latin America and the Caribbean: a scoping review.
Rev Panam Salud Publica
January 2025
Instituto Nacional de Cardiologia Rio de Janeiro Brazil Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil.
Objective: To provide an overview of hospital-based health technology assessment (HB-HTA) activities in Latin America and the Caribbean, including the technologies assessed, resources utilized, evaluation methods employed, and challenges encountered.
Methods: A scoping review focused on HB-HTA using frameworks from the Joanna Briggs Institute was conducted across databases and gray literature.
Results: Seventeen studies were identified, and another two documents were retrieved manually at a conference, totaling 19 files.
Long-Term Real-World Survival of Immunotherapy Compared to Chemotherapy for Metastatic Nonsmall Cell Lung Cancer: A Propensity Score-Matched Analysis.
Thorac Cancer
January 2025
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Article Synopsis
- This study investigates the long-term effects of immunotherapy (IO) for patients with metastatic nonsmall cell lung cancer (mNSCLC), using data from over 10,000 patients.
- The research compared IO to standard treatments, highlighting that IO offers a modest survival benefit, with an average increase of about 3.2 months for first-line therapy and 2.7 months for second-line therapy.
- While IO shows potential to extend overall survival and delay the time to next treatment, the long-term effects are still uncertain compared to clinical trial outcomes.
Enabling participation in community-dwelling children and young people with acquired brain injuries and their families: a theory-based, evidence-based and person-based approach to intervention development.
BMJ Open
December 2024
Centre for Rehabilitation and Ageing Research, University of Nottingham, Nottingham, UK.
Objective: To codesign and develop an intervention to promote participation and well-being in children and young people (CYP) with acquired brain injury (ABI) and family caregivers.
Design: A complex intervention development study including a scoping review, mixed-methods study, co-design workshop and theoretical modelling.
Setting: Community-dwelling participants in one geographical region of the UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!